CO5160296A1 - Nuevas formas de presentacion para agentes activos labiles en medio acido, unidad de agente activo y proceso para la produccion de dicha unidad de agente - Google Patents

Nuevas formas de presentacion para agentes activos labiles en medio acido, unidad de agente activo y proceso para la produccion de dicha unidad de agente

Info

Publication number
CO5160296A1
CO5160296A1 CO00040091A CO00040091A CO5160296A1 CO 5160296 A1 CO5160296 A1 CO 5160296A1 CO 00040091 A CO00040091 A CO 00040091A CO 00040091 A CO00040091 A CO 00040091A CO 5160296 A1 CO5160296 A1 CO 5160296A1
Authority
CO
Colombia
Prior art keywords
agent unit
active
active agent
production
agents
Prior art date
Application number
CO00040091A
Other languages
English (en)
Inventor
Dietrich Rango
Rudolf Linder
Original Assignee
Byk Gulden Lomberg Chem Fab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7910295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO5160296(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Byk Gulden Lomberg Chem Fab filed Critical Byk Gulden Lomberg Chem Fab
Publication of CO5160296A1 publication Critical patent/CO5160296A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una forma de presentación para agentes activos lábiles en medio ácido, que contiene adyuvantes farmacéuticos y unidades individuales múltiples de agente activo, caracterizada porque el agente activo lábil en medio ácido se encuentra en las unidades individuales de agente activo en una matriz constituida por una mezcla que contiene al menos un alcohol graso y al menos una parafina sólida.Igualmente, se refiere a una unidad de agente activo que contiene un agente activo lábil en medio ácido y a un proceso para la producción de dicha una unidad de agente activo.
CO00040091A 1999-06-07 2000-05-30 Nuevas formas de presentacion para agentes activos labiles en medio acido, unidad de agente activo y proceso para la produccion de dicha unidad de agente CO5160296A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19925710A DE19925710C2 (de) 1999-06-07 1999-06-07 Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer

Publications (1)

Publication Number Publication Date
CO5160296A1 true CO5160296A1 (es) 2002-05-30

Family

ID=7910295

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00040091A CO5160296A1 (es) 1999-06-07 2000-05-30 Nuevas formas de presentacion para agentes activos labiles en medio acido, unidad de agente activo y proceso para la produccion de dicha unidad de agente

Country Status (6)

Country Link
AR (1) AR024310A1 (es)
CO (1) CO5160296A1 (es)
DE (1) DE19925710C2 (es)
MY (1) MY138975A (es)
PE (1) PE20010303A1 (es)
TW (1) TWI255720B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10061135C1 (de) * 2000-12-07 2002-11-07 Byk Gulden Lomberg Chem Fab Pharmazeutische Zubereitung in Form einer Paste enthaltend einen säurelabilen Wirkstoff
DE10061138C1 (de) * 2000-12-07 2002-08-14 Byk Gulden Lomberg Chem Fab Pharmazeutische Zubereitung in Form eines Saftes enthaltend einen säurelabilen Wirkstoff
DE10061136C1 (de) * 2000-12-07 2002-10-24 Byk Gulden Lomberg Chem Fab Schnell zerfallende Tablette enthaltend einen säurelabilen Protonenpumpenhemmer
UA80393C2 (uk) * 2000-12-07 2007-09-25 Алтана Фарма Аг Фармацевтична композиція, яка містить інгібітор фде 4, диспергований в матриці
BR0115986A (pt) * 2000-12-07 2003-12-23 Altana Pharma Ag Comprimido de desintegração rápida contendo um ingrediente ativo instável aos ácidos
AU2002234545A1 (en) 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical preparation in the form of a suspension comprising an acid-labileactive ingredient
BR0115985A (pt) 2000-12-07 2003-12-23 Altana Pharma Ag Preparação farmacêutica em forma de uma pasta compreendendo um ingrediente ativo ácido-lábil
DE10061137B4 (de) * 2000-12-07 2016-10-06 Takeda Gmbh Neue pharmazeutische Zubereitung
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US20040213848A1 (en) 2001-09-28 2004-10-28 Shun-Por Li Modified release dosage forms
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
EP1572151A1 (en) * 2002-07-03 2005-09-14 Abbott Laboratories Liquid dosage forms of proton pump inhibitors
DE10244129B4 (de) * 2002-09-23 2006-04-20 Iongate Biosciences Gmbh H+-K+-ATPase-Assay
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
BRPI0406427B8 (pt) 2003-03-10 2021-05-25 Astrazeneca Ab processo para a preparação de roflumilast
TW200503783A (en) * 2003-04-11 2005-02-01 Altana Pharma Ag Oral pharmaceutical preparation for proton pump antagonists
DK1861074T3 (da) 2005-03-16 2013-07-29 Takeda Gmbh Smagsmaskeret doseringsform indeholdende roflumilast
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2725924C3 (de) * 1977-06-08 1980-11-06 Hobeg Hochtemperaturreaktor-Brennelement Gmbh, 6450 Hanau Verfahren zur Herstellung kugelförmiger Teilchen aus niedrigschmelzenden organischen Substanzen
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
JP2681373B2 (ja) * 1988-07-18 1997-11-26 塩野義製薬株式会社 徐放性製剤の製造法

Also Published As

Publication number Publication date
DE19925710C2 (de) 2002-10-10
AR024310A1 (es) 2002-09-25
PE20010303A1 (es) 2001-03-09
TWI255720B (en) 2006-06-01
DE19925710A1 (de) 2000-12-14
MY138975A (en) 2009-08-28

Similar Documents

Publication Publication Date Title
CO5160296A1 (es) Nuevas formas de presentacion para agentes activos labiles en medio acido, unidad de agente activo y proceso para la produccion de dicha unidad de agente
GT199900203A (es) Composiciones de celecoxib.
ES2487496T3 (es) Agente para aliviar el síndrome metabólico
AP2397A (en) Matrix for sustained, invariant and independent release of active compounds.
UY39192A (es) Dispersión sólida, proceso para prepararla y forma de dosificación farmacéutica suministrable por vía oral que la comprende
PE20030733A1 (es) Composiciones de goma de mascar y confiteria con composiciones de agente que elimina manchas encapsulado y procedimientos para su fabricacion y uso
AR057181A1 (es) Nueva forma de dosificacion de combinacion
PT1187601E (pt) Nova forma de preparacao e a administracao compreendendo um inibidor da bomba de protoes instavel em meio acido
BR0111016A (pt) Composições farmacêuticas de liberação sustentada para a administração parenteral de compostos hidrófilos biologicamente ativos
PE20020307A1 (es) Forma de dosificacion de farmaco activada por hidrogel
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
PE20110642A1 (es) Formulaciones antifungicas topicas a base de terbinafina y compuestos similares a terbinafina y metodos de uso
AR044050A1 (es) Utilizacion de ivermectina para el tratamiento de desordenes dermatologicos
AR026189A1 (es) Material activo contenido dentro de microesferas de hidrogel
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
AR031358A1 (es) Combinacion de inhibidores de calpaina y secuestrantes de especies de oxigeno reactivo
CL2004001843A1 (es) Combinacion de (a) al menos un derivado 2,5-dihidrobencenosulfonico, como el dobeilato calcico, etamsilato y persilato, y (b) al menos un modulador de los canales de potasio, composicion farmaceutica que la contiene y uso como medicamento en profilax
GT200400134A (es) Sistemas emulsionantes que contienen derivados de azetidina
AR053144A1 (es) Composicion farmaceutica solida que comprende telitromicina
AR002972A1 (es) Pildoras que tienen una matriz farmaceutica que proporcionan un perfil apropiado de liberacion de la droga, composicion para la preparacion de dichamatriz, proceso para preparar dichas pildoras y formas de dosificacion de dicha composicion.
BRPI0416535A (pt) processo de congelamento por vaporização empregando um extrusor para preparar composições de azitromicina de multiparticulado contendo preferivelmente um poloxámero e um glicerìdeo
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
AR018376A1 (es) Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
HRP20060040A2 (en) PURE D-(17α)-13-ETHYL-17-HYDROXY-18,19-DINORPREGN-4-ENE-20-YNE-3-ONE-3E- AND -3Z-OXIME ISOMERS, AS WELL AS PROCESS FOR THE SYNTHESIS OF THE MIXTURE OF ISOMERS AND THE PURE ISOMERS
AR088871A1 (es) Sistemas dispensadores de geles para el cuidado oral